23:55 , Jul 13, 2017 |  BC Week In Review  |  Company News

Almirall lowers guidance

Almirall S.A. (Madrid:ALM) lowered its 2017 top-line and earnings guidance. The dermatology company now expects 2017 revenues and sales to fall in the low double digits compared to 2016, and it guided to EBITDA of...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

Acticlate doxycycline hyclate regulatory update

Almirall’s Aqua Pharmaceuticals LLC unit said FDA approved an NDA for Acticlate doxycycline hyclate to treat several infections, including adjunctive treatment of severe acne. The company plans to begin marketing the oral tetracycline antibiotic “in...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Clinical News

Doryx doxycycline hyclate delayed-release tablet regulatory update

FDA approved a 200 mg dose of tetracycline oral antibiotic Doryx doxycycline hyclate delayed-release tablet from Mayne's U.S. marketing partner Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland). Warner Chilcott plans to launch the dose in...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Warner Chilcott, Impax, Mylan infectious news

Warner Chilcott said the U.S. District Court for the District of New Jersey ruled in favor of Mylan and Impax in a patent infringement suit brought by Warner Chilcott related to a generic version of...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

Doryx doxycycline hyclate delayed-release tablet regulatory update

FDA accepted for filing a Citizen's Petition from Mayne's marketing partner Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) asking the agency not to grant final approval of ANDAs for generic versions of 150 mg Doryx...
07:00 , Oct 3, 2005 |  BioCentury  |  Finance

Ebb & Flow

As a systemically delivered cancer drug, Genentech's Avastin clearly enjoys premium pricing. But the economics of the antibody, which costs $550 per 100 mg vial, could change dramatically in a non-systemic setting, where much less...
07:00 , Jun 21, 2004 |  BioCentury  |  Strategy

Not just skin deep

Not just skin deep Product Indication Status Company Partner Visudyne Age-related macular degeneration (AMD) Mkt QLT Novartis Eligard leuprolide 1-, 3- and 4-month depot Prostate cancer Mkt ATRX Sanofi-Synthelabo (U.S.); MediGene/Yamanouchi(Europe); Sosei/Nippon(Japan) Eligard...
08:00 , Feb 17, 2004 |  BC Extra  |  Clinical News

CGPI rosacea Phase III data

CollaGenex (CGPI) said preliminary data from a Phase III trial in 134 patients with rosacea showed that Periostat doxycycline hyclate tablets significantly reduced the number of inflammatory lesions compared to placebo (p=0.009). Clinical disease severity...
08:00 , Dec 8, 2003 |  BC Week In Review  |  Company News

Atrix, curasan AG sales and marketing update

curasan received exclusive marketing rights in Germany to Atridox and Atrisorb from ATRX. Atridox is a specific local antibiotic, and Atrisorb is a bioabsorbable membrane that is applied as a liquid. Atrix Laboratories...
08:00 , Jan 13, 2003 |  BC Week In Review  |  Clinical News

Periostat doxycycline tablets and Atridox doxycycline gel: Phase IV

GCPI began a double-blind, placebo-controlled Phase IV trial in ?180 patients of a combination of Periostat and Atridox from Atrix Laboratories Inc. (ATRX, Fort Collins, Colo.). Patients will receive full-mouth scaling and root planing...